Form 4: AnaptysBio Director John A. Orwin Acquires Stock Options and Restricted Stock Units

Director John A. Orwin reports acquisition of stock options and restricted stock units in AnaptysBio, Inc.

Summary

• On January 7, 2025, John A. Orwin, a director of AnaptysBio, Inc., acquired 16,510 stock options with an exercise price of $14.83.
• These options vest monthly, starting February 7, 2025, over a 12-month period, contingent upon continued service to the company, and expire on January 6, 2035.
• Orwin also acquired 6,030 restricted stock units (RSUs), each representing a right to receive one share of AnaptysBio's common stock.
• These RSUs vest 100% on the date of the Issuer's 2026 annual meeting of shareholders, subject to continued service.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects insider confidence through the acquisition of stock options and RSUs, aligning the director's interests with those of the shareholders. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
• The vesting schedules for both the options and RSUs incentivize continued service and commitment to AnaptysBio.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company directors and officers.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock options and RSUs as a positive sign, indicating confidence in the company's future performance.

Key Dates